Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8157303 | 0.97 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL21844964 | 0.97 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL16878033 | 0.94 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL15680849 | 0.94 | — | — | |
| SCHEMBL16503412 | 0.94 | — | — | |
| SCHEMBL21863849 | 0.91 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL16878527 | 0.91 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL16877557 | 0.91 | — | — | |
| SCHEMBL2276672 | 0.90 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL16877902 | 0.88 | ALDH1A1 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044486-A1 | JAK2 INHIBITOR COMPOUNDS | AJAX THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | claimed |
| WO-2024044486-A1 | JAK2 INHIBITOR COMPOUNDS | AJAX THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230347161-A1 | Method and compositions for creating magnetically aligned, bioactive scaffolds for tissue regeneration | DAPPRICH JOHANNES (US) | 2023-11-02 | — | — | US | disclosed |
| US-10544146-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2020-01-28 | — | — | US | disclosed |
| US-10030019-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2018-07-24 | — | — | US | disclosed |
| US-9550793-B2 | Spirocyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-01-24 | — | — | US | disclosed |
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-10 | — | — | US | disclosed |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| WO-2015103583-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2011080755-A1 | FUSED NITROGEN HETEROCYCLIC COMPOUNDS, PROCESS OF PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | MGAM, BPGM, MRPL21 | ALDH1A1 1587/4885 |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | DGAT1, DGAT2, CPT1A | ALDH1A1 307/4885 |
| US-10544146-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NR0B1, NR2E1, NR0B2 | ALDH1A1 1128/4885 |
| US-10030019-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NR0B1, NR2E1, NR0B2 | ALDH1A1 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.